15 Sep 2026 Recon: Experts press FDA to set safety, access standards for psychedelic drugs; GSK to shut German vaccine factory due to low demand Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
14 Sep 2026 Recon: New FDA oncology chief vows continued innovation in OCE; FDA approves drugs for two rare genetic diseases Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
10 Sep 2026 Recon: UK unveils recommendations for regulating AI in medicine; FDA halts new enrollment in Biohaven epilepsy trials Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
08 Sep 2026 Recon: FDA approves AZ’s breast cancer drug over negative adcomm vote; Novartis sees setbacks for drugs targeting cholesterol, myotonic dystrophy Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
03 Sep 2026 Recon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drug Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
01 Sep 2026 Recon: Trump announces new pricing deals with midsize biotechs; Novartis pauses CAR-T trials after patient deaths Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
31 Aug 2026 Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
27 Aug 2026 Recon: FDA weighs new deputy commissioner posts; Trump set to reveal more MFN drug pricing deals Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
25 Aug 2026 Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
24 Aug 2026 Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
